Summit Trail Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit Trail Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454K	Buy	7,932 +2,855	+56%	+$156K	0.01%	1239
2026 Q1	$287K	Sell	5,077 -1,126	-18%	-$65.7K	﹤0.01%	1311
2025 Q4	$369K	Buy	6,203 +686	+12%	+$37.3K	0.01%	1167
2025 Q3	$299K	Buy	+5,517	New	+$316K	﹤0.01%	1207
2018 Q1	–	Sell	-555	Closed	-$51K	–	583
2017 Q4	$51K	Buy	+555	New	+$48.3K	0.01%	811

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Summit Trail Advisors's BMRN Position: Q2 2026 in Review

Summit Trail Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 56% in Q2 2026, buying an estimated $156K and bringing the position to 7,932 shares worth $454K. The position accounts for 0.01% of the portfolio, ranked #1239.

Summit Trail Advisors first reported a position in BMRN in Q4 2017 and has held it in 5 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Summit Trail Advisors held 7,932 shares of BioMarin Pharmaceuticals worth $454K as of Q2 2026.
Summit Trail Advisors bought 2,855 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $156K.
BioMarin Pharmaceuticals made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1239 holding.
Summit Trail Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 5 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.